Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for its magnetic blood purification platform announces a joint feasibility project with the global pharmaceutical company AstraZeneca.
Clinical Development Press Release
hemotune AG initiates joint feasibility project on the HemoSystem with AstraZeneca
Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for [...]
Continue reading
Clinical Development Innovation Press Release
At the forefront of research into prevention of scar tissue formation after a heart attack
Resistell’s first patients recruited for international clinical study [...]
Continue reading
Clinical Development Innovation Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study [...]
Continue reading
Innovation Investment Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Continue reading
Diversity Hemex Team Innovation
Empowering our people, transforming our world in 2023
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue reading
Callum is a student at Gymnasium Liestal. He applied for a one-week internship at HEMEX and has spent the last week accompanying the team during our daily activities. Here’s a sum-up of his week written by Callum himself.
Last week we were honored to organize a Social Media workshop with the startup macu4 where we had a valuable conversation about how beneficial is to define e.g., your strategy, brand awareness, or target group to grow and accelerate your business.
Eating healthier, regular exercise, or reading more books – many people use the New Year to tackle new projects or follow through on old plans. What’s on your list of New Year’s resolutions for 2022?
Apply by January 16 to the Venture Leaders Technology program, where you’ll meet industry leaders and top technology investors in Silicon Valley
Market tracking is not only exciting but has recently become a requirement under the Medical Device regulations (MDR) of the EU. Join us in learning what steps are necessary to complete the post-market clinical follow-up!
Collaboration, Press Release
Resistell AG announces completion of clinical pilot Performance Evaluation Study
We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.
Welcome to the last article of HEMEX’s diversity series! Today we want to introduce you to our newest team member Manuela. Manuela grew up in Basel, Switzerland, and is currently studying medicine at the University of Basel. Curious about what brought her to HEMEX? Let’s keep reading and find out!
The Austrian biotech company is developing endolysins and phages as therapeutics, focusing on persistent bacterial infections that cannot be targeted with broad-spectrum antibiotics. This acquisition is a big step for the AMR crisis and the formerly Phagomed team. At HEMEX, we wanted to congratulate them on their fantastic job!
December 3rd is the international day of people with disabilities. Therefore, on this day, we’d like to raise awareness on the dignity and well-being of persons with disabilities while fostering a deeper understanding of the topic.